This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Morvan syndrome (MoS) is a rare acquired channelopathy associated with autoantibodies against potassium channel complex and clinically characterized by the heterogeneous combination of neuromyotonia, dysautonomia, and encephalopathy.1 Peculiar CNS symptoms are organic insomnia, which ranges from mild to malignant forms characterized by complete loss of sleep, and persistent motor/autonomic hyperactivation (agrypnia excitata2). We describe a patient with MoS who developed progressive agrypnia excitata, in which IV immunoglobulin (IVIg) treatment induced a progressive recovery of the physiologic sleep-wake cycle, documented by videopolysomnography (VPSG) and actigraphic monitoring.
Acknowledgments
Acknowledgment: The authors thank the patient, Francesco Mignani for help in preparing the figures, Elena Zoni for help in preparing the videos, and Cecilia Baroncini for English revision.
Footnotes
↵* All authors contributed equally to this work.
Supplemental data at Neurology.org
Author contributions: Dr. Baiardi: data collection, interpretation of results, preparation of the manuscript. Dr. Provini: data collection, interpretation of results, preparation of the manuscript. Dr. Avoni: data collection, interpretation of results. Dr. Pasquinelli: data collection, interpretation of results. Prof. Liguori: data collection, interpretation of results, preparation of the manuscript.
Study funding: No targeted funding reported.
Disclosure: The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.
- Received December 17, 2014.
- Accepted in final form March 6, 2015.
- © 2015 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker